Skip to main content

Advertisement

Table 8 Randomized Controlled Trials of Glucocorticoids in Prostate Cancer

From: Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy

Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Sander et al [43], 1982 Advanced untreated prostate cancer orchiectomy (7/7) vs. ochiectomy + prednisone 2.5 mg po four times daily for 6 weeks (14/14) vs. ochiectomy + cyproterone acetate 50 mg po four times daily for 6 weeks (13/13) 1 response rates of 86% vs. 93% vs. 62%
Williams et al [59], 1990 Advanced untreated prostate cancer orchiectomy (24/24) vs. orchiectomy + dexamethasone 0.5 mg in morning and 0.3 mg at night (16/16) vs. orchiectomy + cyproterone acetate 100 mg 3 times daily (20/20) 3 response rates of 33% vs. 62.5% vs. 45% at 1 year
Fossa et al [33], 1985 Hormone refractory prostate cancer MPA 500 mg po twice daily (24/21) vs. prednisolone 5 mg po four times daily (24/24) 2 response rates of 38% vs. 13% (p < 0.05), no survival difference
Patel et al [8], 1990 Hormone refractory metastatic prostate cancer Megestrol acetate 40 mg po four times daily (29/25) vs. dexamethasone 0.75 mg po twice daily (29/26), Treatment until PD 2 response rates of 10% vs. 7%, median survival of 268 vs. 246 days (p = 0.2)
Datta et al [35], 1997 Hormone refractory metastatic prostate cancer Flutamide 250 mg three times daily (20/20) vs. prednisolone 5 mg twice daily (20/20) 2 PSA response rates of 50% vs. 55%, median survival of 30 vs. 36 weeks (p > 0.05)
Tyrrell [36, 54, 60], 1996 Hormone refractory advanced prostate cancer prednisone 10 mg po twice daily (103/NR) vs. liarozole 300 mg po twice daily (117/NR) 1 PSA response rates of 25% vs. 18% (p = 0.31); time to PSA progression of 4.7 vs. 3.5 months; median survivals of 15.8 months vs. 11.7 months (p = 0.01)
Fossa et al [32], 2001 Hormone refractory metastatic prostate cancer prednisone 5 mg po four times a day (101/95) vs. flutamide 250 mg po three times a day (100/96); treatment until PD 2 PSA responses of 21% vs. 23%, median time to progression of 3.4 months vs. 2.3 months (p = 0.0885); overall survival of 10.6 months vs. 11.2 months (p = 0.8370)
Tombal et al [50], 2003 Hormone refractory metastatic prostate cancer irofulven (24 mg/m2 for first 18 patients then 0.55 mg/kg for next 43 patients) IV days 1 and 15 q4 weeks (29/28) vs. same + prednisone 10 mg daily (32/28) 1 PSA responses of 3/28 vs. 5/28